ÂÜÀòÂÒÂ×

Dr. Paul Tebbey, Ph.D., M.B.A. is a member of the Board of Directors and Advisor for Radyus Research.

Based in Chicago, IL, Paul serves as Vice-President for US Medical Affairs Biosimilars for Fresenius-Kabi, a global healthcare company, and recently was Vice-President, Oncology, US Medical Affairs, for Abbvie. Paul has 25 years of healthcare experience across the biotechnology and pharmaceutical sectors. Paul received a Ph.D. in Microbiology and Immunology from East Carolina University School of Medicine (Greenville, NC) where his research focused on T lymphocyte cell signaling, immunosuppression, and transformation. Subsequent to his postdoctoral studies at Vanderbilt University (Nashville, TN), which focused on the regulation of gene expression, he then studied for an MBA at Rochester Institute of Technology (Rochester, NY).

Paul spent the majority of his career in large pharmaceutical companies in senior management roles, from Abbvie to Baxter, Centocor/J&J, and Wyeth Vaccines/Pfizer. His research, development, and drug launch experiences include therapeutic monoclonal antibodies (adalimumab, infliximab, and ustekinumab) & antibody-drug conjugates, oncolytics (venetoclax) as well as complex vaccines (conjugated pneumococcal vaccine). He has extensive therapeutic category expertise and extensive opinion leader relationships in therapeutic areas of oncology, dermatology, rheumatology, gastroenterology, neurology, immunology, infectious diseases, and biosimilars.

Paul’s publications include over 40 peer-reviewed articles that span immunology, immune-mediated and infectious diseases, as well as pharmaceutical publication planning and brand success.